HBeAg-negative chronic hepatitis B
Conditions
Interventions
None listed
Sponsors
Gunma University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients in which at least two years have passed since nucleotide analog has been administered. 2. patients with a positive HBsAg, a negative HBeAg, less than 2.1 log copies/ml HBV-DNA. 3. patients and thier family who gave informed consent about the risk or benefit of the study. 4. patients who have more than or equal to 1500/mm3 neutrophils, 90,000/mm3 platelets, and 10 g/dl hemoglobins.
Exclusion criteria
Exclusion criteria: 1. patients receiving Shosaikoto. 2. patients with past history of interstitial pneumonitis. 3. patients with past history of hypersensitivity to peginterferon alpha-2a and other interferons. 4. patients with past history of hypersensitivity to biological products such as vaccine. 5. pregnant women, women who may be expecting a child or lactating woman. 6. patients with chronic renal failure or severe renal dysfunction with less than or equal to 50 mL/min Ccr. 7.patients with severe depression, suicidal thinking or suicide attempt or past history of any of these diseases. 8. patients with severe liver dysfunction. 9. patients with chronic hepatitis such as autoimmune hepatitis and alcoholic hepatitis. 10. patients judged as inappropriate by the attending physician. 11. patients with less than 1.9 LogIU/mL HBsAg and less than 2.9LogIU/mL HBcrAg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| negative conversion of HBsAg | — |
Countries
Japan
Outcome results
None listed